Literature DB >> 30076562

Clinic implication of MUC1 O-glycosylation and C1GALT1 in esophagus squamous cell carcinoma.

Yuming Wang1, Xiaodong Liao2,3, Qing Ye4, Lei Huang5,6.   

Abstract

Esophagus squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors in the world. Our previous data demonstrates that oncoprotein MUC1 is related with metastasis and poor outcome of ESCC. However, alteration of MUC1 in ESCC remains unclear. Using ONCOMINE and COSMIC databases, we analyzed MUC1 gene copy numbers and gene mutations and found that MUC1 had high expression level but few gene mutations in ESCC. Further study of ESCC samples indicated that MUC1 O-glycosylation levels were higher in tumor tissues than that in para-carcinoma tissues in 10 of 14 pairs of ESCC samples. Moreover, we verified a potential link between MUC1 O-glycosylation and C1GALT1, which was further supported by IHC analysis on 38 ESCC and 19 para-carcinoma samples. More importantly, co-expression of MUC1 Oglycosylation and C1GALT1 presented positive correlations with both lymph node metastasis and survival time of ESCC patients. Our work collectively indicates that C1GALT1 is associated with O-glycosylated MUC1 in ESCC, not only suggesting a diagnostic significance of C1GALT1 and MUC1 O-glycosylation in ESCC, but also opening novel insights into targeting C1GALT1 and MUC1 O-glycosylation to suppress ESCC cells metastasis in patients.

Entities:  

Keywords:  CIGALT1; ESCC; MUC1; gene mutation; glycosylation

Mesh:

Substances:

Year:  2018        PMID: 30076562     DOI: 10.1007/s11427-017-9345-7

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  7 in total

1.  LINC00173 promotes Wilms' tumor progression through MGAT1-mediated MUC3A N-glycosylation.

Authors:  Qingliang Zhu; Deming Zhan; Yongguo Yang; Yankun Chong; Haoliang Xue; Peng Zhu
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

2.  Analysis of the correlation of the expression level of hypoxia-inducible factor-1α with the glycosylation of oral squamous cell carcinoma.

Authors:  Xiaoliang Xu; Hui Liu; Ran Wu; Weiwen Zuo; Tiantao Wang; Dong Chen
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 3.  Update on the role of C1GALT1 in cancer.

Authors:  Tong Xia; Ting Xiang; Hailong Xie
Journal:  Oncol Lett       Date:  2022-01-27       Impact factor: 2.967

4.  Construction and investigation of β3GNT2-associated regulatory network in esophageal carcinoma.

Authors:  Zhiguo Luo; Qing Hu; Yuanhui Tang; Yahui Leng; Tian Tian; Shuangyue Tian; Chengyang Huang; Ao Liu; Xinzhou Deng; Li Shen
Journal:  Cell Mol Biol Lett       Date:  2022-01-24       Impact factor: 5.787

Review 5.  Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.

Authors:  Divya Thomas; Ashok Kumar Rathinavel; Prakash Radhakrishnan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-11-04       Impact factor: 10.680

Review 6.  C1GALT1 in health and disease.

Authors:  Xiaojie Sun; Mengru Zhan; Xun Sun; Wanqi Liu; Xiangwei Meng
Journal:  Oncol Lett       Date:  2021-06-06       Impact factor: 2.967

Review 7.  Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology.

Authors:  Elisabete Fernandes; Janine Sores; Sofia Cotton; Andreia Peixoto; Dylan Ferreira; Rui Freitas; Celso A Reis; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Theranostics       Date:  2020-03-31       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.